Sign in Subscribe
Cardiology

AstraZeneca's Crestor: A Breakthrough in Cholesterol Management

Strategic Insights

— 2 min read

Since its FDA approval on August 12, 2003, Crestor (rosuvastatin calcium) has become a crucial treatment option for millions of people worldwide struggling with elevated cholesterol levels. The medication, developed by AstraZeneca, has been proven to be safe and effective in lowering cholesterol levels, with over 1.2 million patients treated and 3.7 million prescriptions dispensed in the US. The American Heart Association estimates that approximately 100 million Americans have total blood cholesterol values of 200 mg/dL and higher, with about 40 million adults having levels of 240 or above.

Key Takeaways:

  • Crestor has been prescribed to over 1.2 million patients, with 3.7 million prescriptions dispensed in the US since its approval in 2003.
  • The medication has been shown to be a safe and effective treatment option, with over 8 out of 10 patients reaching their LDL-C goal at a 10 mg starting dose.
  • The National Cholesterol Education Program interim guidelines recommend that physicians help patients at moderate and very high risk for cardiovascular disease reach even lower LDL or "bad" cholesterol levels.
  • AstraZeneca's chairperson Catherine Bonuccelli emphasized the critical importance of managing cholesterol levels, highlighting statin therapy as one of the most effective ways to achieve this goal.
  • Patients like Geoff Capes, a 39-year-old director of technology in New York, have successfully reduced their cholesterol levels with Crestor, achieving healthy levels within the first 5 weeks of taking the medication.
  • Clinical trials have demonstrated that Crestor 10 mg provides more effective LDL-C reduction than 10 mg of atorvastatin and is a logical first choice drug therapy for patients with elevated cholesterol not responding to diet and exercise.
  • Crestor has been shown to lower LDL-C by over 50% at a low 10 mg dose and raise HDL-C or "good" cholesterol between 8 and 14% across the dosage range.
  • Lipidologist Tom Rifai, MD, from Northpointe Health Center in Berkley, Michigan, noted that statin monotherapy remains the foundation of lipid management and that Crestor is an effective product for achieving optimal LDL and HDL levels.

Statistics:

  • Over 1.2 million patients have been treated with Crestor since its FDA approval in 2003.
  • Approximately 3.7 million prescriptions for Crestor have been dispensed in the US.
  • The American Heart Association estimates that approximately 100 million Americans have total blood cholesterol values of 200 mg/dL and higher.
  • About 40 million American adults have total blood cholesterol levels of 240 or above.
  • Crestor has been shown to lower LDL-C by over 50% at a low 10 mg dose.
  • HDL-C or "good" cholesterol is raised between 8 and 14% across the dosage range.

Sources:

  • AstraZeneca
  • American Heart Association
  • National Cholesterol Education Program
  • Crestor clinical trials
  • Catherine Bonuccelli, MD, VP, external scientific affairs, AstraZeneca
  • Tom Rifai, MD, a leading lipidologist and board-certified physician nutrition specialist from Northpointe Health Center in Berkley, Michigan
  • Geoff Capes, a 39-year-old director of technology in New York

Read more